These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 20940397)

  • 1. Peptide vaccination after T-cell transfer causes massive clonal expansion, tumor eradication, and manageable cytokine storm.
    Ly LV; Sluijter M; Versluis M; Luyten GP; van Stipdonk MJ; van der Burg SH; Melief CJ; Jager MJ; van Hall T
    Cancer Res; 2010 Nov; 70(21):8339-46. PubMed ID: 20940397
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Skewing the T-cell repertoire by combined DNA vaccination, host conditioning, and adoptive transfer.
    Jorritsma A; Bins AD; Schumacher TN; Haanen JB
    Cancer Res; 2008 Apr; 68(7):2455-62. PubMed ID: 18381454
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vaccination with an adenoviral vector encoding the tumor antigen directly linked to invariant chain induces potent CD4(+) T-cell-independent CD8(+) T-cell-mediated tumor control.
    Sorensen MR; Holst PJ; Pircher H; Christensen JP; Thomsen AR
    Eur J Immunol; 2009 Oct; 39(10):2725-36. PubMed ID: 19637230
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Decreased specific CD8+ T cell cross-reactivity of antigen recognition following vaccination with Melan-A peptide.
    Appay V; Speiser DE; Rufer N; Reynard S; Barbey C; Cerottini JC; Leyvraz S; Pinilla C; Romero P
    Eur J Immunol; 2006 Jul; 36(7):1805-14. PubMed ID: 16761313
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effective cooperation of monoclonal antibody and peptide vaccine for the treatment of mouse melanoma.
    Ly LV; Sluijter M; van der Burg SH; Jager MJ; van Hall T
    J Immunol; 2013 Jan; 190(1):489-96. PubMed ID: 23203930
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Persistence, immune specificity, and functional ability of murine mutant ras epitope-specific CD4(+) and CD8(+) T lymphocytes following in vivo adoptive transfer.
    Bristol JA; Schlom J; Abrams SI
    Cell Immunol; 1999 May; 194(1):78-89. PubMed ID: 10357883
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Concurrent allorecognition has a limited impact on posttransplant vaccination.
    Manzo T; Hess Michelini R; Basso V; Ricupito A; Chai JG; Simpson E; Bellone M; Mondino A
    J Immunol; 2011 Feb; 186(3):1361-8. PubMed ID: 21209285
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vivo plasmid electroporation induces tumor antigen-specific CD8+ T-cell responses and delays tumor growth in a syngeneic mouse melanoma model.
    Kalat M; Küpcü Z; Schüller S; Zalusky D; Zehetner M; Paster W; Schweighoffer T
    Cancer Res; 2002 Oct; 62(19):5489-94. PubMed ID: 12359758
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Defining the ability of cyclophosphamide preconditioning to enhance the antigen-specific CD8+ T-cell response to peptide vaccination: creation of a beneficial host microenvironment involving type I IFNs and myeloid cells.
    Salem ML; Kadima AN; El-Naggar SA; Rubinstein MP; Chen Y; Gillanders WE; Cole DJ
    J Immunother; 2007 Jan; 30(1):40-53. PubMed ID: 17198082
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of IL-2- versus IL-15-stimulated CD8 T cells in adoptive immunotherapy.
    Mueller K; Schweier O; Pircher H
    Eur J Immunol; 2008 Oct; 38(10):2874-85. PubMed ID: 18825743
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [New strategy of cancer immunotherapy: irradiation or chemotherapeutics-induced lymphopenia combined with immune reconstitution and tumor vaccine].
    Ma J; Wang YL; Hu HM; Fox BA; Si LS
    Zhonghua Zhong Liu Za Zhi; 2005 Aug; 27(8):452-6. PubMed ID: 16188138
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapy of established tumors in a novel murine model transgenic for human carcinoembryonic antigen and HLA-A2 with a combination of anti-idiotype vaccine and CTL peptides of carcinoembryonic antigen.
    Saha A; Chatterjee SK; Foon KA; Celis E; Bhattacharya-Chatterjee M
    Cancer Res; 2007 Mar; 67(6):2881-92. PubMed ID: 17363612
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Allogeneic GM-CSF-secreting tumor cell immunotherapies generate potent anti-tumor responses comparable to autologous tumor cell immunotherapies.
    Li B; Simmons A; Du T; Lin C; Moskalenko M; Gonzalez-Edick M; VanRoey M; Jooss K
    Clin Immunol; 2009 Nov; 133(2):184-97. PubMed ID: 19664962
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of antitumor immune responses in reconstituted lymphopenic hosts.
    Hu HM; Poehlein CH; Urba WJ; Fox BA
    Cancer Res; 2002 Jul; 62(14):3914-9. PubMed ID: 12124318
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Induction of an antigen cascade by diversified subcutaneous/intratumoral vaccination is associated with antitumor responses.
    Kudo-Saito C; Schlom J; Hodge JW
    Clin Cancer Res; 2005 Mar; 11(6):2416-26. PubMed ID: 15788693
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-tumor T cell response and protective immunity in mice that received sublethal irradiation and immune reconstitution.
    Ma J; Urba WJ; Si L; Wang Y; Fox BA; Hu HM
    Eur J Immunol; 2003 Aug; 33(8):2123-32. PubMed ID: 12884286
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biodistribution and vaccine efficiency of murine dendritic cells are dependent on the route of administration.
    Eggert AA; Schreurs MW; Boerman OC; Oyen WJ; de Boer AJ; Punt CJ; Figdor CG; Adema GJ
    Cancer Res; 1999 Jul; 59(14):3340-5. PubMed ID: 10416590
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effective treatment of preexisting melanoma with whole cell vaccines expressing alpha(1,3)-galactosyl epitopes.
    Rossi GR; Mautino MR; Unfer RC; Seregina TM; Vahanian N; Link CJ
    Cancer Res; 2005 Nov; 65(22):10555-61. PubMed ID: 16288048
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of a ras oncogene peptide that contains both CD4(+) and CD8(+) T cell epitopes in a nested configuration and elicits both T cell subset responses by peptide or DNA immunization.
    Bristol JA; Orsini C; Lindinger P; Thalhamer J; Abrams SI
    Cell Immunol; 2000 Nov; 205(2):73-83. PubMed ID: 11104579
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined alpha tumor necrosis factor gene therapy and engineered dendritic cell vaccine in combating well-established tumors.
    Liu Y; Saxena A; Zheng C; Carlsen S; Xiang J
    J Gene Med; 2004 Aug; 6(8):857-68. PubMed ID: 15293344
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.